Education
About Us
Working with TipRanks
Follow Us
Atea Pharmaceuticals, Inc. (AVIR)
:AVIR
AVIR Stock Chart & Stats
$3.05
$0.04(1.19%)
At close: 4:00 PM EST
$3.05
$0.04(1.19%)
Day’s Range― - ―
52-Week Range$2.46 - $4.02
Previous CloseN/A
Volume180.19K
Average Volume (3M)424.40K
Market Cap
$238.29M
Enterprise Value-$99.01M
Total Cash (Recent Filing)$329.31M
Total Debt (Recent Filing)$1.04M
Price to Earnings (P/E)―
Beta0.71
Next Earnings
Mar 03, 2026EPS Estimate
-0.49Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.53
Shares Outstanding78,126,790
10 Day Avg. Volume455,210
30 Day Avg. Volume424,396
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)0.64
Price to Sales (P/S)0.00
P/FCF Ratio-2.08
Enterprise Value/Market Cap-0.42
Enterprise Value/Revenue-238.01
Enterprise Value/Gross Profit17.52
Enterprise Value/Ebitda0.62
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.64
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Antiviral DevelopmentIND-enabling studies are ongoing for two nucleotide prodrug development candidates, AT-2490 and AT-587, for the treatment of immunocompromised patients living with hepatitis E virus (HEV).
Commercial Market OpportunityThe company's management outlined a significant commercial market opportunity for its Hepatitis C treatments.
Unmet Medical NeedAtea Pharmaceuticals highlighted the differentiation and unmet medical need for its Hepatitis C treatments during a virtual KOL panel event.
Bears Say
Financial PerformanceAtea reported a net loss of $42.1 million, or a loss of $0.53 per share, which was worse than our estimate of a loss of $37.0 million, or a loss of $0.44 per share.
Atea Pharmaceuticals News
AVIR FAQ
What was Atea Pharmaceuticals, Inc.’s price range in the past 12 months?
Atea Pharmaceuticals, Inc. lowest stock price was $2.46 and its highest was $4.02 in the past 12 months.
What is Atea Pharmaceuticals, Inc.’s market cap?
Atea Pharmaceuticals, Inc.’s market cap is $238.29M.
When is Atea Pharmaceuticals, Inc.’s upcoming earnings report date?
Atea Pharmaceuticals, Inc.’s upcoming earnings report date is Mar 03, 2026 which is in 85 days.
How were Atea Pharmaceuticals, Inc.’s earnings last quarter?
Atea Pharmaceuticals, Inc. released its earnings results on Nov 12, 2025. The company reported -$0.53 earnings per share for the quarter, missing the consensus estimate of -$0.415 by -$0.115.
Is Atea Pharmaceuticals, Inc. overvalued?
According to Wall Street analysts Atea Pharmaceuticals, Inc.’s price is currently Overvalued.
Does Atea Pharmaceuticals, Inc. pay dividends?
Atea Pharmaceuticals, Inc. does not currently pay dividends.
What is Atea Pharmaceuticals, Inc.’s EPS estimate?
Atea Pharmaceuticals, Inc.’s EPS estimate is -0.49.
How many shares outstanding does Atea Pharmaceuticals, Inc. have?
Atea Pharmaceuticals, Inc. has 78,126,790 shares outstanding.
What happened to Atea Pharmaceuticals, Inc.’s price movement after its last earnings report?
Atea Pharmaceuticals, Inc. reported an EPS of -$0.53 in its last earnings report, missing expectations of -$0.415. Following the earnings report the stock price went down -12.571%.
Which hedge fund is a major shareholder of Atea Pharmaceuticals, Inc.?
Currently, no hedge funds are holding shares in AVIR
Atea Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
― (―)
― (―)
Blogger Sentiment
Bullish
AVIR Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 45.2K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Negative
20 days / 200 days
Momentum
-7.57%
12-Months-Change
Fundamentals
Return on Equity
-37.98%
Trailing 12-Months
Asset Growth
-30.14%
Trailing 12-Months
Company Description
Atea Pharmaceuticals, Inc.
Atea Pharmaceuticals (AVIR) is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics. The company's primary area of focus is on oral direct-acting antiviral therapies to treat life-threatening viral infections, with its lead product candidate being AT-527 for the treatment of COVID-19.
AVIR Company Deck
AVIR Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in the HCV Phase III program, strong financial health, and promising new research findings. Challenges include an increase in R&D expenses and a decrease in interest income. Overall, the sentiment is predominantly positive due to the outweighing highlights.View all AVIR earnings summariesAVIR Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Ownership Overview
10.42% Insiders
14.72% Mutual Funds
22.68% Other Institutional Investors
41.04% Public Companies and
Individual Investors